Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Equity Income (2021 - 2025)

Precision Biosciences (DTIL) has disclosed Equity Income for 5 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Income rose 338.0% to $2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$573000.0, a 112.84% decrease, with the full-year FY2024 number at $258000.0, down 77.47% from a year prior.
  • Equity Income was $2.5 million for Q3 2025 at Precision Biosciences, up from -$2.5 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $3.5 million in Q4 2023 to a low of -$2.5 million in Q2 2025.
  • A 5-year average of -$11187.5 and a median of -$219000.0 in 2021 define the central range for Equity Income.
  • Peak YoY movement for Equity Income: soared 2993.33% in 2022, then crashed 455.04% in 2025.
  • Precision Biosciences' Equity Income stood at -$90000.0 in 2021, then skyrocketed by 2993.33% to $2.6 million in 2022, then surged by 36.1% to $3.5 million in 2023, then crashed by 118.59% to -$659000.0 in 2024, then skyrocketed by 479.51% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Equity Income are $2.5 million (Q3 2025), -$2.5 million (Q2 2025), and $49000.0 (Q1 2025).